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To determine whether the cardiovascular effect of
1,25(OH)2D is dependent on calcium and/or phosphorus,
mice with targeted deletion of the 25(OH)D 1a-hydroxylase
and their wild-type littermates were fed a normal diet or a
diet to rescue the ambient serum calcium and phosphorus
levels. Mice on the normal diet were treated daily with
vehicle or 1,25(OH)2D3 while mice on the rescue diet
received vehicle, captopril or losartan. After four weeks the
vehicle-treated knockout mice developed hypertension,
cardiac hypertrophy and impaired cardiac function along
with an up-regulation of the renin-angiotensin system in
both renal and cardiac tissues. Although the serum calcium
and phosphorus levels were normalized in knockout mice
on the rescue diet, abnormalities in blood pressure, cardiac
structure-function and the renin-angiotensin system
remained. In contrast, 1,25(OH)2D3 not only normalized
serum calcium and phosphorus levels but also normalized
blood pressure, cardiac structure-function and the
renin-angiotensin system. Treatment of the knockout mice
with either captopril or losartan normalized blood pressure
and cardiac structure and function although renin expression
remained elevated. This study shows that 1,25(OH)2D plays
a protective role in the cardiovascular system by repressing
the renin-angiotensin system independent of extracellular
calcium or phosphorus.
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The most well-known function of 1,25(OH)2D is to maintain
calcium and phosphorus homeostasis and to promote
bone mineralization. However, apart from these traditional
calcium-related actions, 1,25(OH)2D3 and its synthetic
analogs are being increasingly recognized for their potent
antiproliferative, pro-differentiation, and immunomodu-
latory activities. The actions of 1,25(OH)2D are mediated
mostly through the vitamin D receptor (VDR). Physiological
and pharmacological actions of 1,25(OH)2D3 in various
systems, along with detection of VDR in various target cells,
suggest potential therapeutic applications of VDR ligands
in osteoporosis, cancer, secondary hyperparathyroidism, and
autoimmune diseases.1 Furthermore, recent evidence indi-
cates that the vitamin D endocrine system also plays a critical
role in regulation of blood pressure, volume homeostasis,
and cardiac function.2–5
Previous studies reported that the serum level of
1,25(OH)2D3 is inversely associated with blood pressure in
normotensive and hypertensive subjects;6–8 it is also inversely
correlated with plasma renin activity in patients with essen-
tial hypertension.9 A recent epidemiological study of a
large normotensive population in the United States also
found an inverse association between serum vitamin D levels
and blood pressure.10 In clinical trials, vitamin D treatment
reduced blood pressure in hypertensive or elderly patients.11,12
Administration of 1,25(OH)2D3 has also been reported to
reduce blood pressure, plasma renin activity, angiotensin II
(Ang II) levels, and myocardial hypertrophy.5,13,14 The
clinical and epidemiological evidence therefore suggests that
vitamin D may regulate blood pressure via regulating the
renin–angiotensin system (RAS).
Recently, Li et al. investigated the role of vitamin D in
the cardiovascular system by employing a mouse model
with targeted ablation of the VDR gene (VDR/).2,4,15
They found that both renin mRNA and protein levels in the
kidney, as well as plasma Ang II production, were drastically
increased in VDR/ mice.2 More recently they have found
that 1,25(OH)2D3 suppresses renin gene transcription by
blocking the activity of the cyclic AMP-response element
in the renin gene promoter.16 As a consequence of aberrant
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RAS over-stimulation, VDR/ mice developed hyperten-
sion, cardiac hypertrophy, and excess-drinking behavior.
Plasma and urinary aldosterone levels were also increased
in VDR/ mice.4,17 Their data suggest that 1,25(OH)2D3
acts as a negative endocrine regulator of renin production
in vivo. However, the effect of 1,25(OH)2D3 deficiency on the
cardiovascular system has not been fully explored in animals.
We18 and others19 have previously reported a mouse
model deficient in 1,25(OH)2D by targeted ablation of the
1a(OH)ase gene (1a(OH)ase/). These mice developed
hypocalcemia, hypophosphatemia, secondary hyperpara-
thyroidism, and skeletal abnormalities characteristic of
rickets. These abnormalities are similar to those reported
in VDR/ mice,15,20,21 except that VDR/ mice also deve-
loped alopecia. In this study, we used 1a(OH)ase/ mice to
assess the effect of 1,25(OH)2D deficiency on the RAS, blood
pressure, and cardiac function. Our data demonstrate that
hypertension induced by vitamin D deficiency can lead to
detrimental effects on cardiac function, that treatment with
1,25(OH)2D3 can reverse these findings, and that the effect of
1,25(OH)2D3 on the cardiovascular system is calcium- and
phosphorus-independent.
RESULTS
Effect of 1,25(OH)2D3 deficiency on systolic blood pressure,
cardiomyocytes, and cardiac systolic function
Both systolic blood pressure (Figure 1a) and heart weight-
to-body weight ratio were increased significantly (Figure 1b)
in 1a(OH)ase/ mice compared with their wild-type litter-
mates. The left ventricles and cardiomyocytes were markedly
hypertrophic in 1a(OH)ase/ mice, as demonstrated by
cross sections of the ventricles (Figure 1c) and the cardio-
myocyte morphology (Figure 1d). Quantitative data confir-
med that the thickness of interventricular septum (Figure 1e)
and cardiomyocyte diameters (Figure 1f) were increased
significantly in 1a(OH)ase/ mice. Echocardiographic
analyses (Figure 2a) revealed that the interventricular septum
thickness diastolic (IVSd; Figure 2b), the relative wall thick-
ness (RWT; Figure 2c), and left-ventricular mass (LVM)
relative to body weight (Figure 2d) were also increased in
1a(OH)ase/ mice; however, indices of cardiac systolic
function, including fractional shorting (FS; Figure 2e) and
ejection fraction (EF; Figure 2f) were reduced in 1a(OH)ase/
mice compared with wild-type mice. These results demonstrate
that 1,25(OH)2D3 deficiency leads to hypertension, cardiac
hypertrophy, and impaired cardiac systolic function in mice.
Effect of 1,25(OH)2D3 deficiency on the renal RAS
To determine whether hypertension and cardiac hypertrophy
in 1a(OH)ase/ mice were associated with the activation
of the RAS, plasma renin, Ang II, and aldosterone levels
were determined by radioimmunoassay, renal renin, and
angiotensinogen (Aogen) mRNA levels were examined by
real-time reverse transcription-polymerase chain reaction
(RT-PCR) and renal renin protein levels were determined by
western blotting. Plasma levels of renin (Figure 3a), Ang II
(Figure 3b), and aldosterone (Figure 3c) were increased by
more than 1.5-fold, and renal renin mRNA (Figure 3d) and
protein levels (Figure 4a and b) and Aogen mRNA levels
(Figure 3e) were markedly upregulated in 1a(OH)ase/
mice compared with wild-type mice. These results demon-
strate that 1,25(OH)2D3 deficiency leads to upregulation of
the RAS in mice.
Cardiac abnormalities and RAS overactivation cannot
be rescued by normalization of ambient calcium and
phosphorus levels in 1a(OH)ase/ mice
To determine whether cardiac abnormalities and upregu-
lation of RAS can be corrected by normalization of ambient
calcium and phosphorus levels in 1a(OH)ase/ mice,
6-week-old, sex-matched, wild-type and 1a(OH)ase/ mice
were fed a ‘rescue diet’ diet containing 2% calcium, 1.25%
phosphorus, and 20% lactose for 4 weeks before analyses.
The rescue diet normalized serum calcium and phosphorus
levels in the mutant mice (Figure 4c and d), but failed to
normalize the blood pressure (Figure 1a), cardiac hyper-
trophy (Figures 1b–f and 2a–d), cardiac systolic function
(Figure 2e and f), and upregulation of the RAS (Figure 3
and 4a and b) seen in 1a(OH)ase/ mice. These findings
indicate that cardiac abnormalities and activation of the RAS
associated with 1,25(OH)2D3 deficiency are independent of
the calcium and phosphorus status in mice.
Cardiac abnormalities and the RAS are normalized by
administration of 1,25(OH)2D3 in 1a(OH) ase
/ mice
To determine whether cardiac abnormalities and upregula-
tion of RAS in 1a(OH)ase/ mice can be normalized by
administration of 1,25(OH)2D3, 6-week-old, sex-matched,
wild-type and 1a(OH)ase/ mice on the normal diet were
treated daily with vehicle or 62.5 ng 1,25(OH)2D3/mouse for
4 weeks. As expected, 1,25(OH)2D3 treatment normalized
serum calcium and phosphorus levels in 1a(OH)ase/ mice
(Figure 4c and d). 1,25(OH)2D3 also reduced blood pressure
(Figure 1a), cardiac hypertrophy (Figures 1b–f and 2a), and
normalized cardiac systolic function (Figure 2e and f) in
mutant mice. Moreover, levels of plasma renin (Figure 3a),
Ang II (Figure 3b), and aldosterone (Figure 3c), as well as
that of renin mRNA (Figure 3d) and protein (Figure 4a and
b) and Aogen mRNA (Figure 3e), were reduced significantly
in 1a(OH)ase/ mice by administration of 1,25(OH)2D3
compared wit vehicle-treated 1a(OH)ase/ mice. These
findings demonstrate that although 1,25(OH)2D deficiency
leads to activation of the RAS and cardiovascular abnorm-
alities, these abnormalities can be effectively treated with
1,25(OH)2D3.
Cardiac abnormalities are rescued by captopril or losartan
in 1a(OH)ase/ mice
Given that Ang II is the central effector of the RAS, we
assessed whether cardiac abnormalities can be corrected by
administration of the angiotensin-converting enzyme inhi-
bitor captopril or the Ang-a type 1 receptor antagonist
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Figure 1 | Hypertension and cardiac hypertrophy in 1a(OH) ase/ mice. After weaning sex-matched wild-type (1a(OH)aseþ /þ ) and
1a(OH)ase/ mice were fed a normal diet or a ‘rescue diet’ diet. After 3 weeks on a normal diet, eight animals of each genotype received
daily treatment of vehicle (ND), or 62.5 ng 1,25(OH)2D3, intraperitoneally (VD) for four subsequent weeks. After 3 weeks on the ‘rescue diet’,
eight animals of each genotype received vehicle (RD) or 100 mg kg1 captopril (Cap) or 30 mg kg1 losartan (Losa). At the end of this
time period, systolic blood pressure (a) and heart weight-to-body weight (HW/BW) ratio (b) were measured. Representative micrographs of
the cross sections of the ventricles (c) and the longitudinal sections of cardiomyocytes (d) are shown. The thickness of interventricular
septum (IVS) (e) and cardiomyocyte diameters (f) were measured and presented as percentage of wild-type values. Each value is the
means±s.e.m. of determinations in eight mice of each group. *Po0.05; **Po0.01; ***Po0.001 compared with vehicle-treated wild-type
mice. wPo0.05; wwwPo0.001 compared with vehicle-treated mice fed with the normal diet (ND). #Po0.05; ###Po0.001 compared with
vehicle-treated mice fed with a ‘rescue diet’ (RD).
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Figure 2 | Cardiac hypertrophy and impaired cardiac systolic function in 1a(OH)ase/ mice. (a) Representative graphs of
echocardiography from each group described in Figure 1. The parameters of echocardiography were measured and calculated as described
under Materials and Methods. (b) IVSd. (c) RWT. (d) LVM relative to BW. (e) FS. (f) EF. Each value is the means±s.e.m. of determinations
in eight mice of each group. *Po0.05; **Po0.01; ***Po0.001 compared with vehicle-treated wild-type mice. wPo0.05; wwPo0.01;
wwwPo0.001 compared with vehicle-treated mice fed with the normal diet (ND). #Po0.05; ##Po0.01; ###Po0.001 compared with
vehicle-treated mice fed with a ‘rescue diet’ (RD).
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losartan in 1a(OH)ase/ mice. The 6-week-old, sex-matched,
wild-type and 1a(OH)ase/ mice on the ‘rescue diet’ were
treated with the vehicle, 100 mg kg1 captopril, or with
30 mg kg1 losartan daily for 4 weeks; systolic blood pressure
was measured and cardiac structure, systolic function, and
the RAS parameters were examined. Results showed that
blood pressure (Figure 1a), cardiac hypertrophy (Figure 1b–f,
Figure 2a–d), cardiac systolic function (Figure 2e and f), and
plasma aldosterone levels (Figure 3c) in 1a(OH)ase/ mice
were normalized by captopril or losartan. Compared with the
rescue diet control, both captopril and losartan increased
plasma renin (Figure 3a), renal renin mRNA (Figure 3d), and
protein (Figure 4a and b) levels in wild-type mice because of
their disruption of the feedback inhibition loop in renin
synthesis; as a result, plasma renin, and renin mRNA and
protein levels were even more elevated in these 1a(OH)ase/
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Figure 3 | Upregulation of the RAS in 1a(OH)ase/ mice. Mice from each group were treated as described in Figure 1. The peripheral
blood was harvested and plasma was separated. Plasma renin (a), Ang II (b), and aldosterone (c) were determined by radioimmunoassay.
Renal renin (d) and Aogen (e) mRNA levels were examined by real-time RT-PCR. The renal renin and Aogen mRNA levels were calculated as
a ratio to the GAPDH mRNA level and expressed relative to levels of vehicle-treated wild-type mice fed with the normal diet (ND) or a
‘rescue diet’ (RD). Each value is the means±s.e.m. of determinations in eight mice of each group. *Po0.05; **Po0.01; ***Po0.001
compared with vehicle-treated wild-type mice. wPo0.05; wwPo0.01; wwwPo0.001 compared with vehicle-treated mice fed with the
normal diet (ND). #Po0.05; ##Po0.01; ###Po0.001 compared with vehicle-treated mice fed with a ‘rescue diet’ (RD).
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mice (Figures 3a, d and 4a, b). Plasma Ang II (Figure 3b) and
Aogen mRNA levels (Figure 3e) were reduced significantly by
captopril in wild-type mice, but were not altered by losartan,
in both wild-type and 1a(OH)ase/ mice. These findings
confirm that the cardiac abnormalities seen in 1a(OH)ase/
mice are mainly caused by over-activation of the RAS, and
1,25(OH)2D3 protects the cardiovascular system through
repression of the RAS cascade.
Effect of 1,25(OH)2D3 deficiency on the expression of
VDR and 1a(OH)ase and the RAS in cardiac tissue
We first determined whether the VDR and 1a(OH)ase
were expressed in cardiac tissue. The results showed that VDR
mRNA (Figure 5a) was detectable by real-time RT-PCR in both
1a(OH)ase/ mice and wild-type mice, whereas 1a(OH)ase
mRNA was found only in wild-type mice (Figure 5b).
We next determined whether cardiac hypertrophy in
1a(OH)ase/ mice was associated with activation of the
cardiac RAS. Cardiac renin and Aogen mRNA levels were
examined by real-time RT-PCR and cardiac renin protein
levels were determined by western blotting. Results showed
that cardiac renin mRNA (Figure 5c) and protein levels
(Figure 5e and f) and Aogen mRNA levels (Figure 5d) were
markedly upregulated in 1a(OH)ase/ mice compared
with wild-type mice. The rescue diet failed to normalize
the upregulation of the cardiac RAS (Figure 5c–f) seen in
1a(OH)ase/ mice. The level of cardiac renin mRNA
(Figure 5c) and protein (Figure 5e and f) and Aogen mRNA
(Figure 5d) were reduced significantly in 1a(OH)ase/ mice
by administration of 1,25(OH)2D3 compared with the
vehicle-treated 1a(OH)ase/ mice. These results demon-
strate that 1,25(OH)2D3 not only regulates the renal RAS,
but also regulates the cardiac RAS in mice in a calcium-
independent and 1,25(OH)2D3-dependent manner.
DISCUSSION
In this study, we employed a genetic approach to determine
the effect of 1,25(OH)2D3 deficiency on the cardiovascular
system. Our data demonstrate that mice deficient in
1,25(OH)2D3 synthesis with targeted ablation of the
1a(OH)ase gene developed hypertension, cardiac hypertro-
phy, and impaired cardiac systolic function, due to activation
of the RAS. Administration 1,25(OH)2D3 to 1a(OH)ase
/
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Figure 4 | Levels of renin protein and serum calcium and phosphorus. (a) Representative western blots of renal extracts to determine
renin protein levels. b-Tubulin was used as loading control. (b) Renal renin protein levels relative to b-tubulin protein levels were
assessed by densitometric analysis and expressed as percentage of the levels of vehicle-treated wild-type mice fed the normal diet (ND)
or a ‘rescue diet’ (RD), respectively. (c) Serum calcium and (d) phosphorus were determined as described under Materials and Methods.
Each value is the means±s.e.m. of determinations in eight mice of each group. *Po0.05; **Po0.01; ***Po0.001; compared with
vehicle-treated wild-type mice. wPo0.05; wwPo0.01; wwwPo0.001 compared with vehicle-treated mice fed with the normal diet
(ND). ###Po0.001 compared with vehicle-treated mice fed with a ‘rescue diet’ (RD).
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levels, but also normalized the RAS, blood pressure, cardiac
hypertrophy, and cardiac functions. However, normalization
of serum calcium and phosphorus in 1a(OH)ase/ mice with
dietary means failed to normalize the RAS and the cardiac
abnormalities. These results indicate that 1,25(OH)2D3
regulates the RAS and cardiac function by a calcium- and
phosphorus-independent mechanism.
The RAS plays a central role in regulation of blood pres-
sure and water/salt balance under physiological conditions.
Renin is the rate-limiting enzyme that converts Aogen to
angiotensin I, which is then converted by angiotensin-
converting enzyme to Ang II, the central effector of the
RAS. Ang II increases salt retention and blood pressure by
stimulating aldosterone secretion and by increasing vaso-
constriction. A pivotal involvement of the RAS in the
pathophysiology of cardiovascular disease is supported by a
large body of basic and clinical evidence.22–25 Over-stimula-
tion of the RAS leads to hypertension, cardiac hypertrophy,
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Figure 5 | Expression of 1a(OH)ase and VDR in cardiac tissue and the effect of 1,25(OH)2D3 deficiency on the cardiac RAS. The
cardiac VDR (a) and 1a(OH)ase (b) mRNA levels were examined by real-time RT-PCR in vehicle-treated wild-type and 1a(OH)ase/ mice fed
a normal diet (ND). The cardiac VDR and 1a(OH)ase mRNA levels were calculated as a ratio relative to the GAPDH mRNA level. The cardiac
renin (c) and Aogen (d) mRNA levels were examined by real-time RT-PCR. The cardiac renin and Aogen mRNA levels were calculated as a
ratio relative to the GAPDH mRNA level and expressed relative to levels in vehicle-treated wild-type mice fed with the normal diet (ND).
(e) Representative western blots of cardiac extracts to determine renin protein levels. b-Tubulin was used as a loading control. (f) Cardiac
renin protein levels relative to b-tubulin protein levels were assessed by densitometric analysis and expressed as percentage of the levels
of vehicle-treated wild-type mice fed the normal diet (ND). Each value is the means±s.e.m. of determinations in eight mice of each
group. *Po0.05; **Po0.01 compared with vehicle-treated wild-type mice. wPo0.05 compared with vehicle-treated mice fed with the
normal diet (ND).
176 Kidney International (2008) 74, 170–179
o r i g i n a l a r t i c l e CL Zhou et al.: Vitamin D regulation of the renin–angiotensin system
and impaired cardiac activity. Most of the pathological effect
of Ang II is mediated via its binding to the AT1 receptor on the
plasma membrane.26 The key role of Ang II involved in the
mechanism of diseases is strongly corroborated by a large
number of interventional studies. In fact, pharmacologic inter-
ference of RAS activity, by both preventing Ang II formation
with angiotensin-converting enzyme inhibitors or by block-
ing its binding to cell membrane receptors with selective
antagonists, is associated with highly beneficial outcomes in
major disease conditions, including hypertension, renal failure,
heart failure, myocardial infarction, stroke, and others.27 In
this study, we showed that accompanying the hypertension,
cardiac hypertrophy, and impaired cardiac systolic function in
1a(OH)ase/ mice was upregulation of the RAS. Renin
mRNA and protein expression, and plasma renin, Ang II, and
aldosterone levels were all markedly elevated in the mutant
mice relative to their wild-type littermates. Remarkably, blood
pressure, cardiac hypertrophy, and cardiac function were
normalized not only by the administration of captopril or
losartan, but also by 1,25(OH)2D3. In 1a(OH)ase
/ mice;
1,25(OH)2D3 treatment suppressed renin expression, whereas
treatment with captopril or losartan led to further increases in
renin production, due to interruption of the feedback
inhibition of renin production by these compounds. These
data provide strong evidence that cardiac abnormalities in
1a(OH)ase/ mice are a consequence of over-activation of
the RAS, and that 1,25(OH)2D3 plays a protective role in the
cardiovascular system by suppressing the RAS.
Our previous studies using 1a(OH)ase/ mice showed
that parathyroid gland size and development of the cartila-
ginous growth plate are each regulated by calcium and
1,25(OH)2D3, but independent of the VDR, whereas para-
thyroid hormone secretion and mineralization of bone were
dependent on ambient calcium levels, but were independent
of the 1,25(OH)2D/VDR system.
28 Thus, although the
phenotypes of the 1a(OH)ase/ mice and VDR/ mice
in the skin, parathyroid glands, and cartilaginous growth
plate are not completely identical,28 the phenotypes in the
cardiovascular system are similar in both mutant animal
models. This is very strong evidence that 1,25(OH)2D3
regulates cardiovascular functions via the VDR.
Our data are consistent with previous reports that
showed that mice with targeted ablation of the VDR gene
also develop hypertension and cardiac hypertrophy due to
upregulation of the RAS,2,4 and our studies emphasize
the detriment to cardiac function, which ensues in vitamin
D-deficient animals. In clinical studies, it has previously been
reported that administration of 1,25(OH)2D3 to hypertensive
or elderly patients leads to reduction in blood pressure and
myocardial hypertrophy.11–14 In chronic kidney disease
patients on hemodialysis, treatment with active vitamin D
analogs significantly reduced the risk of cardiovascular
death,29 although the exact mechanism of action underlying
the beneficial effect of the vitamin D has been unclear.
Previous studies have shown that cardiac RAS activation
plays a major role underlying the structural and functional
abnormalities associated with genetic sympathetic hyper-
activity-induced heart failure in mice,30 and the cardiac
hypertrophy seen in VDR/ mice is a consequence of acti-
vation not only of the systemic, but also of the cardiac RAS.4
Our results demonstrated that cardiac renin mRNA and
protein levels and Aogen mRNA levels were markedly upregu-
lated in 1a(OH)ase/ mice compared with wild-type mice,
and were not normalized by dietary high calcium and
phosphate, but were reduced significantly in 1a(OH)ase/
mice by administration of 1,25(OH)2D3 compared with
vehicle-treated 1a(OH)ase/ mice. These results support the
notion that 1,25(OH)2D3 not only regulated the renal RAS,
but also regulated the cardiac RAS in mice in a calcium-
independent and 1,25(OH)2D3-dependent manner, and that
1,25(OH)2D3 regulates cardiac functions, at least partially,
through the cardiac RAS.
Recently VDR has been found in adult rat cardiac
myocytes primarily localized to the t-tubule,31 and we also
demonstrated mRNA expression of the VDR in cardiac tissue.
In addition, we demonstrated mRNA expression of the
1a(OH)ase enzyme in cardiac tissue. This suggests that local
conversion of 25 hydroxyvitamin D to 1,25(OH)2D3 may
occur and that 1,25(OH)2D3 may then act in a para-
crine, autocrine, or intracrine manner to modulate cardiac
function such as the cardiac RAS. Nevertheless, in the model
of global inactivation of the 1a(OH)ase we employed, the
effects we observed on the rescue of both the cardiac
and renal RAS were clearly due to circulating 1,25(OH)2D3
added exogenously. It remains to be determined what the
relative contributions might be of circulating endogenous
1,25(OH)2D3 provided by renal synthesis, relative to local
1,25(OH)2D3 provided by cardiac conversion of 25hydroxy-
vitamin D. It also remains to be determined whether the
activity of the cardiac 1a(OH)ase enzyme might be impaired
in cardiac disease or might be impaired in renal failure.
However, in the model of global inactivation of the
1a (OH)ase we used, both cardiac and renal enzymes were
inactivated and exogenously administered circulating
1,25(OH)2D3 was clearly effective in rescuing the impaired
RAS phenotype. These studies, and those by others,2,4,5
demonstrating the efficacy of circulating 1,25(OH)2D3 on
the cardiovascular system may now provide an explanation
for the reduction in blood pressure and myocardial
hypertrophy in hypertensive and elderly patients, and
the decreased cardiovascular mortality of chronic kidney
disease patients receiving systemic administration of active
vitamin D forms.29
In summary, we demonstrate in this study that genetically
mutant mice deficient in 1,25(OH)2D3 biosynthesis develop
hypertension, cardiac hypertrophy, and impaired cardiac
systolic function due to the over-stimulation of the renal and
cardiac RAS. 1,25(OH)2D3 regulates renin biosynthesis and
cardiovascular function by a calcium- and phosphorus-
independent mechanism in vivo. Our data obtained from
1a(OH)ase/ mice are consistent with, as well as confirm,
the cardiovascular abnormalities of VDR/ mice reported
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previously, and provide new data on the detrimental effect of
vitamin D deficiency on cardiac function, thus strengthening
the notion that vitamin D plays a protective role in the
cardiovascular system. These studies also provides hope for a
useful and beneficial intervention in patients with potentially
defective cardiac 1a (OH)ase and in those who have kidney
failure.
MATERIALS AND METHODS
Animals and treatment
The generation and characterization of 1a(OH)ase/ mice were
previously described by Panda et al.18 1a(OH)ase/ Mice were
generated through breeding of heterozygous mice and identified by
PCR with tail genomic DNA as the template, and wild-type litter-
mates were used as controls in all the experiments. The use of
animals in this study was approved by the Institutional Animal Care
and Use Committee of the University.
Forty pairs of age- and gender-matched 1a(OH)ase/ and
wild-type littermates were randomly divided into five groups. After
weaning they were fed a normal diet or a ‘rescue diet’ diet containing
2% calcium, 1.25% phosphorus, and 20% lactose (Harlan Teklad,
Madison, WI, USA) for 3 weeks. For four subsequent weeks, animals
on the normal diet received daily treatment of the vehicle or 62.5 ng
of 1,25(OH)2D3 intraperitoneally, and animals on the ‘rescue diet’
received the vehicle, 100 mg kg1 captopril, an inhibitor of angio-
tensin-converting enzyme, or 30 mg kg1 losartan, an Ang II type I
receptor antagonist, by daily gavage.
Measurements of blood pressure
Systolic blood pressure was measured in conscious animals using a
noninvasive computerized tail-cuff system (ML125 NIBP system;
Powerlab, AD Instruments, Castle Hill, NSW, Australia). Mice were
placed in plastic restrainers. A cuff with a pneumatic pulse sensor
was attached to the tail. Mice were allowed to habituate to this
procedure for 7 days before the measurement of systolic blood
pressure. To obtain accurate blood pressure reading, mice remained
at a still and unperturbed status throughout the measuring period.
Conditioning occurred more readily when mice were handled gently
and not forced to enter the restraint. The chamber was kept at
31–33 1C. Systolic blood pressure was measured during three
consecutive days. Ten separate determinations of systolic blood
pressure were made over a 10-min interval and the determinations
recorded were averaged.
Echocardiographic analysis
Transthoracic echocardiography was performed using a 14.0-MHz
imaging transducer (GE Ultrasound Machine Vivid 7). Mice from
each group were anesthetized by peritoneal injection with 5 ml g1 of
7.5% chloral hydrate. The left hemithorax of each mouse was shaved
carefully and the heart was imaged in the two-dimensional mode in
the parasternal long-axis view. From this view, an M-mode cursor
was positioned perpendicular to the interventricular septum and
posterior wall of the left ventricle at the level of the papillary
muscles, and M-mode images were obtained for measurements
of wall thickness and chamber dimensions. Left-ventricular end-
diastolic dimension (LVDd), left-ventricular end-systolic dimension
(LVDs), left-ventricular posterior wall thickness diastolic (LVPWd),
IVSd, and heart rate were measured. All measurements were
performed using the leading edge-to-leading edge convention
adopted by the American Society of Echocardiography. EF was
calculated by Teichholz formula. Percent FS, LVM, and RWT were
calculated as follows:
FS ¼ ½ðLVDd  LVDsÞ=LVDd100
LVM ¼ 1:055½ðLVDd þ IVSd þ LVPWdÞ3  LVDd3
RWT ¼ ðIVSd þ LVPWdÞ=LVDd
Measurement of blood parameters
Serum calcium and phosphate and 1,25(OH)2D3 levels were
measured as described previously.28 Mouse plasma renin, angio-
tensin II (Ang II), and aldosterone concentrations were determined
by radioimmunoassay, using commercial radioimmunoassay kits.
The procedures were preformed according to the manufacturer’s
instructions.
Determination of heart-to-body weight ratio and histological
analysis
The body weight and the weight of the freshly dissected hearts were
measured and the ratio of heart weight to body weight was
calculated. The whole heart was fixed in a 4% formaldehyde-
phosphate-buffered saline (pH 7.4) solution overnight. The cardiac
atria were removed by cutting through the coronary sulcus and the
cardiac ventricles were embedded in wax and cut into 5-mm cross
sections along the cutting face below the coronary sulcus using a
rotary microtome. Serial sections of ventricles were collected every
50 mm, stained with hematoxylin—eosin, and examined under a
regular microscope. The interventricular septum thickness and the
diameter of the cardiomyocytes were measured using Northern
Eclipse image analysis software.
Western blot analysis
The kidney and heart were dissected and immediately placed into
radioimmunoprecipitation assay lysis buffer containing a cocktail
for proteinase inhibitors for protein extraction. Protein extracts
from the kidneys from each group were boiled for 5 min in the
sample buffer and fractionated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred to nitrocellulose
membranes. The membrane was blocked for 3 h at room
temperature with 5% non-fat dry milk in phosphate-buffered
saline/Tween 20. The blots were incubated overnight at 4 1C with
monoclonal antibodies against renin (Fitzgerald, Hornby, Ontario,
Canada), followed by incubation for 1 h with anti-mouse secondary
antibody (horseradish peroxidase conjugated). Immunoreactive
bands were visualized using enhanced chemiluminescence with
ECL reagent treatment and exposure to hyperfilm-ECL. The
intensity of the bands was measured using Image J version 1.29.
RNA isolation and real-time RT-PCR
RNA was isolated from mouse kidney and heart using Trizol reagent
(Invitrogen Inc., Carlsbad, CA, USA) according to the manufac-
turer’s protocol. The mRNA levels of renin and Aogen in the kidney
and heart and the mRNA levels of 1a(OH)ase and VDR were
quantified by real-time RT-PCR.32 Briefly, first-strand cDNAs were
synthesized from 2 mg of total kidney RNAs in a 25-ml reaction using
Moloney murine leukemia virus reverse transcriptase and oligo(dT)
as the primer. The cDNAs were then used as the template (1ml per
reaction) for real-time PCR amplification. Real-time PCR was
carried out using an Applied Biosystems Cycler and a SYBR Green
PCR reagent kit (Toyobo Co., Osaka, Japan). The PCR primers for
mouse renin, Aogen, 1a(OH)ase, VDR, and glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH) genes are shown in Table 1.
GAPDH was used as the internal control for each reaction. All
primers were tested for their specificity by conventional RT-PCR
before being used for real-time RT-PCR quantitative studies.
A melting curve was used to identify a temperature where only
the amplicon, and not primer dimers, accounted for the SYBR
green-bound fluorescence. Results were analyzed with the SDS 7500
software and the relative amount of mRNA was normalized to
GAPDH mRNA.
Statistical analysis
Data are presented as means±s.e.m. Statistical comparisons were
made using a one-way analysis of variance, with Po0.05 being
considered significant.
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Table 1 | Real-time RT-PCR primers used with their name,
orientation (S, sense; AS, antisense), sequence, annealing
temperature (Tm), and length of amplicon (bp)
Name S/AS Sequence Tm (1C) bp
Renin S GAGGCCTTCCTTGACCAATC 64 188
AS TGTGAATCCCACAAGCAAGG
Aogen S CACCCCTGCTACAGTCCATTG 64 221
AS GTCTGTACTGACCCCCTCCAG
1a(OH)ase S GCAGAGGCTCCGAAGTCTTC 55 774
AS TGTCTGGGACACGGGAATTC
VDR S GGCTTCCACTTCAACGCTATG 61 388
AS CTTACGTCTGCACGAATTGG
GAPDH S CATTTCACTCAAGGTTGTCAGC 64 346
AS ATCATACTTGGCAGGTTTCTCC
Aogen, angiotensinogen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
RT-PCR, reverse transcription-polymerase chain reaction; VDR, vitamin D receptor.
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